Genitourinary Cancer Research

Genitourinary Cancer Research

Research into genitourinary and prostate cancer at Penn State Cancer Institute is conducted by the genitourinary cancer team. See current clinical trials and members of that team here.

Clinical Trials

Patient perceptions regarding routine oncologic follow-up for urologic malignancies.
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Use of a Multiplexed Molecular Biomarker Test Cxbladder, in Real World Decision Making to Provide Clinical Utility Using a Randomized Design
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer
Phase 2 Study of Bladder-SparIng ChemoradiatioN with CIPosItive bladdeR cancEr (INSPIRE)EA8185
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Renal Cell Cancer (PDIGREE)
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
A phase 1b, Open-label Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Cell Carcinoma
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer EA8171
Evaluation of Biomarkers in Bladder Cancer Patients in the Neoadjuvant Setting
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)
COVID-19 Vaccination in Cancer Patients COVID-19 Vaccination Behavior and Outcomes in Cancer Patients
A Phase III Double Blinded Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Enhancing Patient Resilience During Multimodal Therapy for Bladder Cancer
Creation of a Clinical and Pathologic Tissue Microarray Registry for Radical Cystectomy Specimens
Complications in Patients Undergoing Radical Cystectomy for Bladder Cancer

Disease Team Members

Research into genitourinary and prostate cancer at Penn State Cancer Institute is conducted by the genitourinary cancer team. See current clinical trials and members of that team here.
Patient perceptions regarding routine oncologic follow-up for urologic malignancies.
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Use of a Multiplexed Molecular Biomarker Test Cxbladder, in Real World Decision Making to Provide Clinical Utility Using a Randomized Design
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer
Phase 2 Study of Bladder-SparIng ChemoradiatioN with CIPosItive bladdeR cancEr (INSPIRE)EA8185
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Renal Cell Cancer (PDIGREE)
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
A phase 1b, Open-label Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Cell Carcinoma
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer EA8171
Evaluation of Biomarkers in Bladder Cancer Patients in the Neoadjuvant Setting
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)
COVID-19 Vaccination in Cancer Patients COVID-19 Vaccination Behavior and Outcomes in Cancer Patients
A Phase III Double Blinded Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Enhancing Patient Resilience During Multimodal Therapy for Bladder Cancer
Creation of a Clinical and Pathologic Tissue Microarray Registry for Radical Cystectomy Specimens
Complications in Patients Undergoing Radical Cystectomy for Bladder Cancer

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)